News

Masitinib study misses endpoint
Enlarge image

Clinical trailsFrance

Masitinib study misses endpoint

01.11.2012 - French AB Science’s cancer drug Masitinib failed to improve overall survival in a Phase III study. But certain patient groups might benefit from the treatment.

The double-blind, international Phase III trial enrolled 348 patients with pancreatic cancer and compared masitinib plus Gemzar treatment with Gemzar treatment alone. There was no significant change in the overall survival time of the patients (7.7 vs. 7 months, p=0.74), said the French drugmaker. But in a subgroup of patients with an undisclosed genetic biomarker which is thought to be indicative of aggressive disease progression, the orally administered tyrosine kinase inhibitor masitinib plus Gemzar significantly improved median overall survival vs. placebo plus Gemzar (11 vs. 5 months, p=0.000038). In a second subgroup of patients with a pain intensity level above an undisclosed threshold at baseline, the orphan drug plus Gemzar also significantly improved median overall survival vs. placebo plus Gemzar (8.1 vs. 5.4 months, p=0.01). These two independent patient populations represented 65% and 45%, respectively, of the overall population, according to AB Science.

AB Science also announced that the European Medicines Agency (EMA) has accepted to review the Marketing Authorization Application (MAA) for conditional approval of masitinib in combination with Gemzar in the treatment of non-resectable, advanced adenocarcinoma pancreatic cancer „ on the basis of results from a Phase III study that showed masitinib in combination with Gemzar significantly extends overall survival in two independent patient populations having the worst prognosis.“ Masitinib targets the stem cell factor (SCF) receptor tyrosine kinase (CD117).

Masitinib has been available in Europe since the second part of 2009 as a treatment of mast cell tumors in animals (Masivet), specifically dogs. In the US it is distributed under the name Kinavet by AB Science and has been available for veterinaries since 2011.

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2012-04/masitinib-study-misses-endpoint.html

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Clinical ResearchFrancePortugal

21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.

Immuno-oncologyNetherlandsBelgium

21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.

RegulatorySwitzerlandEU

20.04.2016 The US government is forking out up to US$100m to get Basilea Pharmaceutica’s broad-spectrum antibiotic ceftobiprole on the US market. In the EU, ceftobiprole is already available.

Immuno-oncologyUK

19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.

FinancingSwitzerlandFranceEUGermanyDenmark

15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.

Event ReviewSwitzerlandBelgiumEU

13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

München

BioVaria 2016

Berlin (GER)

XIV. BIONNALE 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • KAROLINSKA (S)7.85 SEK9.03%

FLOP

  • PROTHENA PLC (IE)38.59 USD-7.15%
  • MEDIGENE (D)8.15 EUR-6.21%
  • ADOCIA (F)56.55 EUR-5.10%

TOP

  • SYNAIRGEN (UK)35.00 GBP45.8%
  • BIOFRONTERA (D)3.24 EUR38.5%
  • SWEDISH ORPHAN BIOVITRUM (S)15.24 USD27.5%

FLOP

  • EVOCUTIS (UK)0.05 GBP-28.6%
  • THERAMETRICS (CH)0.03 CHF-25.0%
  • SERODUS (N)1.50 NOK-23.9%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)28.40 SEK1793.3%
  • NICOX (F)8.27 EUR339.9%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.30 SEK-87.9%
  • BB BIOTECH (D)44.10 EUR-83.1%
  • CYTOS (CH)0.25 CHF-80.3%

No liability assumed, Date: 04.05.2016